February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights
On January 23, 2020, the FDA accelerated the approval of tazemetostat (Tazverik; Epizyme Inc), an EZH2 methyltransferase blocker, for the treatment of patients aged ≥16 years with metastatic or locally advanced epithelioid sarcoma (a subtype of soft-tissue sarcoma) that is not eligible for complete resection. Tazemetostat received an orphan drug designation for this indication.
Read Article
Orlando, FL—The impact of poverty and low socioeconomic status on health and survival among children may be even more debilitating than suspected, according to new data presented at ASH 2019. Even in clinical trials, which are designed to provide consistent treatment across groups, socioeconomic status was associated with “substantial” differences in survival, researchers were surprised to find out.
Read Article
Orlando, FL—Mosunetuzumab is an investigational bi-specific T-cell engager (BiTE) agent dually targeting 2 proteins on the surface of lymphoma cells—CD3 (on the surface of T-cells) and CD20 (on the surface of B-cells).
Read Article
On December 18, 2019, the FDA accelerated the approval of enfortumab vedotin-ejfv (Padcev; Astellas Pharma), a Nectin-4–directed antibody and microtubule inhibitor conjugate, for the treatment of adults with locally advanced or metastatic urothelial cancer after immunotherapy with a PD-1 or PD-L1 inhibitor and a platinum-containing chemotherapy. These are the current standard treatments for patients with bladder cancer, the sixth most common cancer in the United States. Urothelial cancer accounts for >90% of bladder cancers.
Read Article
Orlando, FL—Tazemetostat (Tazverik), a first-in-class, oral, selective EZH2 inhibitor, has demonstrated single-agent antitumor activity in patients with relapsed or refractory follicular lymphoma, according to results of a phase 2 clinical trial presented at ASH 2019.
Read Article
Patients with anemia and lower-risk
myelodysplastic syndromes (MDS) in
whom first-line erythropoiesis-stimulating
agents (ESAs) are not effective
generally become transfusion dependent.
Luspatercept-aamt (Reblozyl), a
recombinant fusion protein that binds
transforming growth factor beta superfamily
ligands to reduce SMAD2 and
SMAD3 signaling, was approved by
the FDA in November 2019 and has
been studied in this patient population
with promising results.
Read Article
Orlando, FL—Nivolumab (Opdivo) monotherapy can be used as an effective bridge therapy to autologous stem-cell transplant (ASCT) in many patients with relapsed or refractory Hodgkin lymphoma, reported Matthew Mei, MD, Assistant Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, at ASH 2019.
Read Article
Orlando, FL—The combination of the BCL2 inhibitor venetoclax (Venclexta) and intensive chemotherapy has demonstrated notable results in fit patients with newly diagnosed or relapsed or refractory acute myeloid leukemia (AML), according to results from a phase 1b/2 single-center clinical trial presented at ASH 2019.
Read Article
Orlando, FL—The combination of duvelisib (Copiktra) plus venetoclax (Venclexta) is a promising all-oral regimen for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Read Article
The discontinuation of oral oncology
medications before the full-month
supply has been finished results in
medication waste, leading to increased
costs for patients and for payers. Split
fills allow for a 14- to 16-day supply for
oral oncology medications rather than
a full 28- to 30-day supply. Researchers
compared the discontinuation rates,
patient-reported adverse events, estimated
pharmacy costs, and potential
waste in patients with pharmacy benefit
designs that included a split-fill option
with patients who did not have
this option (Staskon FC, et al. J Oncol
Pract. 2019;15:e856-e862).
Read Article